{"id":451554,"date":"2021-03-05T01:03:21","date_gmt":"2021-03-05T06:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451554"},"modified":"2021-03-05T01:03:21","modified_gmt":"2021-03-05T06:03:21","slug":"illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/","title":{"rendered":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia"},"content":{"rendered":"

<\/p>\n

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia<\/b><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–
\nIllumina, Inc.\u2019s (NASDAQ: ILMN) NextSeq\u2122 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq\u2122Dx which was approved previously as a medical device. Both of these in vitro<\/i> diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology. These registrations will catalyze the expansion of sequencing-based clinical diagnostics across the country.\n<\/p>\n

\nSequencing platforms, and the reagents that drive them, must be approved separately in Russia by the medical device regulatory agency, Roszdravnadzor. Illumina\u2019s strategic partner in Russia and CIS, R-Pharm, led the regulatory process and this is the first approval of complete sets of sequencing instruments plus reagents.\n<\/p>\n

\n\u201cHaving the two IVD-platforms available to assay developers to expand the clinical use of Next Generation Sequencing-based (NGS) molecular diagnostics will be a great boost to testing for genetic diseases and oncology in Russia,\u201d said Paula Dowdy, Senior Vice President and General Manager of Illumina, Europe Middle East and Africa. \u201cThe NextSeq 550Dx is ideal for high throughput sequencing at large, federal hospitals, and the desktop MiSeqDx is well suited to the laboratory facilities of standard clinical centers.\u201d\n<\/p>\n

\n\u201cThese registrations are a significant step in bringing NGS technologies closer to patients, many of whom live near the smaller municipal and regional clinics. Bringing NGS diagnostics, with accurate and validated results, will be a huge benefit to patients,\u201d said deputy Director General of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Professor Mikhail Maschan.\n<\/p>\n

\nDirector of the Tomsk National Research Medical Center, correspondent member of the Russian Academy of Sciences, Vadim Stepanov, said: \u201cGenetics and molecular biology are the core of clinical science because the majority of diseases originate from genetic mechanisms in cells, tissues and organs. Registration of Illumina\u2019s products as medical devices allows to add the most modern technologies to clinical practice.\u201d\n<\/p>\n

\n\u201cWe are pleased that our partnership with Illumina, a global leader in human genome sequencing, will help Russian patients benefit from improved diagnosis and precision healthcare,\u201d said Alexey Repik, R-Pharm Chairman of the Board.\n<\/p>\n

About R-Pharm<\/b><\/p>\n

\nR-Pharm Group introduces comprehensive solutions for the healthcare system and focuses on research, development, manufacturing and commercialization of pharmaceuticals, laboratory equipment and medical devices. R-Pharm’s mission is to increase the accessibility of advanced diagnostics, preventative care and therapy methods in Russia and abroad. More than 4500 employees of the group in 70 branches and 30 countries of the world do their best to provide as many people as possible with the necessary means to improve and prolong their lives. To learn more, visit www.rpharm.com<\/a>.\n<\/p>\n

About Illumina<\/b><\/p>\n

\nIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com<\/a> or connect with us on Twitter<\/a>, Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a>, and YouTube<\/a>.\n<\/p>\n

Use of forward-looking statements <\/b><\/p>\n

\nThis release contains forward-looking statements that involve risks and uncertainties, including the expectation for lower costs related to the storing and managing of genomic data costs. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, especially in international jurisdictions; (ii) our ability to deploy new products, services, and applications, and to expand the markets for our technology platforms; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations once deployed, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts\u2019 expectations, or to provide interim reports or updates on the progress of the current quarter.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210304005222\/en\/<\/a><\/span><\/p>\n

\nIllumina
\n
Investor Relations
\n
Juliet Cunningham
\n
858.200.6583
\n
IR@illumina.com
\n<\/a><\/p>\n

Media
\n
Dr. Karen Birmingham
\n
646.355.2111
\n
kbirmingham@illumina.com<\/a><\/p>\n

KEYWORDS:<\/b> Europe United States North America Russia California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Biotechnology Research Oncology Health Medical Devices Genetics Other Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc.\u2019s (NASDAQ: ILMN) NextSeq\u2122 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq\u2122Dx which was approved previously as a medical device. Both of these in vitro diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology. These registrations will catalyze the expansion of sequencing-based clinical diagnostics across the country. Sequencing platforms, and the reagents that drive them, must be approved separately in Russia by the medical device regulatory agency, Roszdravnadzor. Illumina\u2019s strategic partner in Russia and CIS, R-Pharm, led the regulatory process and this is the first … <\/p>\n

Continue reading “Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451554","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIllumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc.\u2019s (NASDAQ: ILMN) NextSeq\u2122 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq\u2122Dx which was approved previously as a medical device. Both of these in vitro diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology. These registrations will catalyze the expansion of sequencing-based clinical diagnostics across the country. Sequencing platforms, and the reagents that drive them, must be approved separately in Russia by the medical device regulatory agency, Roszdravnadzor. Illumina\u2019s strategic partner in Russia and CIS, R-Pharm, led the regulatory process and this is the first … Continue reading "Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T06:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia\",\"datePublished\":\"2021-03-05T06:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/\"},\"wordCount\":772,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/\",\"name\":\"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-05T06:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/","og_locale":"en_US","og_type":"article","og_title":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk","og_description":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc.\u2019s (NASDAQ: ILMN) NextSeq\u2122 550Dx platform and associated reagent kits received medical device registration in Russia, as have reagents for the MiSeq\u2122Dx which was approved previously as a medical device. Both of these in vitro diagnostic (IVD)-ready solutions are available to customers and third-party developers to create diagnostic solutions using the technology. These registrations will catalyze the expansion of sequencing-based clinical diagnostics across the country. Sequencing platforms, and the reagents that drive them, must be approved separately in Russia by the medical device regulatory agency, Roszdravnadzor. Illumina\u2019s strategic partner in Russia and CIS, R-Pharm, led the regulatory process and this is the first … Continue reading \"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T06:03:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia","datePublished":"2021-03-05T06:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/"},"wordCount":772,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/","name":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-05T06:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210304005222r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/illumina-and-r-pharm-secure-registration-for-two-complete-ivd-sequencing-platforms-in-russia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451554"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451554\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}